Phraxis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Phraxis is a private, commercial-stage medical device company that has developed and received FDA approval for the EndoForce™ Connector, a novel implant for creating endovascular venous anastomoses in hemodialysis access procedures. The technology replaces traditional surgical suturing with a transcatheter-deployed device, demonstrating a 92% cumulative patency rate in its pivotal trial, which surpasses the historical standard. Led by CEO and inventor Dr. Alex Yevzlin, the company is positioned to address significant clinical challenges in renal care by streamlining AVG creation and improving long-term outcomes for dialysis patients. Phraxis is now focused on the commercial rollout and adoption of its first product.

CardiovascularRenal

Technology Platform

Patented endovascular anastomosis implant system (EndoForce™) for minimally invasive creation of venous connections for arteriovenous grafts, utilizing a nitinol-based design and transcatheter delivery.

Opportunities

The large and growing global dialysis patient population presents a substantial addressable market for a device that improves AVG patency and reduces re-interventions.

The shift towards minimally invasive procedures in interventional nephrology and vascular surgery creates a favorable environment for adoption of endovascular solutions like EndoForce™.

Positive clinical data and FDA approval provide a strong foundation for market entry and potential expansion into adjacent vascular anastomosis applications.

Risk Factors

Commercial success hinges on convincing physicians to adopt a new technique and securing adequate reimbursement from payers.

The company faces competition from established surgical methods and potential new entrants from larger medical device firms.

As a small, private company, Phraxis is vulnerable to execution missteps and capital constraints during the costly commercial launch phase.

Competitive Landscape

Phraxis competes primarily against the entrenched standard of care: open surgical creation of sutured venous anastomoses for AVGs. It also competes indirectly with technologies promoting arteriovenous fistula (AVF) creation, which is clinically preferred when possible. There are few, if any, directly comparable FDA-approved endovascular anastomosis devices for AVG, potentially giving Phraxis a first-mover advantage in this niche, but it may face future competition from larger vascular access companies.

More companies in Drug Delivery & Formulation →More companies in United States →